capsule
Orforglipron
emergingOral
First oral non-peptide GLP-1 agonist in late-stage trials. A daily pill alternative to injectable GLP-1s with promising early weight loss data.
Key facts
- Classification
- Capsule — First oral non-peptide GLP-1 agonist in late-stage trials.
- Primary benefits
- Fat Loss (9/10) · Gut Health (3/10)
- Administration
- Oral
- Doses studied
- 12-36-120 mg oral daily in the morning. Titrate up gradually.
- Evidence strength
- Emerging
Goal coverage · Orforglipron
🔥 Fat Loss9/10
🫃 Gut Health3/10